BP reduction with the sodium glucose co-transporter 2 inhibitor (SGLT-2i) empagliflozin (EMPA) in type 2 diabetes (T2D) is similar in treatment naïve as in those on one or ≥2 anti…
G Mancia, CP Cannon, I Tikkanen, C Zeller, L Ley, T Hach, HJ Woerle, UC Broedl, OE Johansen · Diabetologie und Stoffwechsel · 2015 · Heft 04
Bibliografische Angaben
Zusammenfassung
Objective: EMPA is a new glucose-lowering agent of the SGLT2i class, which reduces body weight and also lowers BP. We assessed the EMPA-related BP lowering effect under background antihypertensive treatment. Methods: This was a 12-week study involving 823 T2D patients (mean ± SD age 60.2 ± 9.0 years, HbA1c 7.9 ± 0.7%, office systolic (S)/diastolic (D) BP 142.1 ± 12.3/83.9 ± 7.0 mmHg, in the full analysis set). EMPA was given at 10 mg (n = 276) or 25 mg (n = 276) daily; 271 patients were randomized to placebo. Patients were under no (A), 1 (B) or ≥2 antihypertensive drugs (C) (n = 62, 353 and 408, respectively).…
